OBJECTIVE: To report clinical and immunological investigations of contactin-associated protein-like 2 (Caspr2), an autoantigen of encephalitis and peripheral nerve hyperexcitability (PNH) previously attributed to voltage-gated potassium channels (VGKC). METHODS: Clinical analysis was performed on patients with encephalitis, PNH, or both. Immunoprecipitation and mass spectrometry were used to identify the antigen and to develop an assay with Caspr2-expressing cells. Immunoabsorption with Caspr2 and comparative immunostaining of brain and peripheral nerve of wild-type and Caspr2-null mice were used to assess antibody specificity. RESULTS: Using Caspr2-expressing cells, antibodies were identified in 8 patients but not in 140 patients with several types of autoimmune or viral encephalitis, PNH, or mutations of the Caspr2-encoding gene. Patients' antibodies reacted with brain and peripheral nerve in a pattern that colocalized with Caspr2. This reactivity was abrogated after immunoabsorption with Caspr2 and was absent in tissues from Caspr2-null mice. Of the 8 patients with Caspr2 antibodies, 7 had encephalopathy or seizures, 5 neuropathy or PNH, and 1 isolated PNH. Three patients also had myasthenia gravis, bulbar weakness, or symptoms that initially suggested motor neuron disease. None of the patients had active cancer; 7 responded to immunotherapy and were healthy or only mildly disabled at last follow-up (median, 8 months; range, 6-84 months). INTERPRETATION: Caspr2 is an autoantigen of encephalitis and PNH previously attributed to VGKC antibodies. The occurrence of other autoantibodies may result in a complex syndrome that at presentation could be mistaken for a motor neuron disorder. Recognition of this disorder is important, because it responds to immunotherapy.
OBJECTIVE: To report clinical and immunological investigations of contactin-associated protein-like 2 (Caspr2), an autoantigen of encephalitis and peripheral nerve hyperexcitability (PNH) previously attributed to voltage-gated potassium channels (VGKC). METHODS: Clinical analysis was performed on patients with encephalitis, PNH, or both. Immunoprecipitation and mass spectrometry were used to identify the antigen and to develop an assay with Caspr2-expressing cells. Immunoabsorption with Caspr2 and comparative immunostaining of brain and peripheral nerve of wild-type and Caspr2-null mice were used to assess antibody specificity. RESULTS: Using Caspr2-expressing cells, antibodies were identified in 8 patients but not in 140 patients with several types of autoimmune or viral encephalitis, PNH, or mutations of the Caspr2-encoding gene. Patients' antibodies reacted with brain and peripheral nerve in a pattern that colocalized with Caspr2. This reactivity was abrogated after immunoabsorption with Caspr2 and was absent in tissues from Caspr2-null mice. Of the 8 patients with Caspr2 antibodies, 7 had encephalopathy or seizures, 5 neuropathy or PNH, and 1 isolated PNH. Three patients also had myasthenia gravis, bulbar weakness, or symptoms that initially suggested motor neuron disease. None of the patients had active cancer; 7 responded to immunotherapy and were healthy or only mildly disabled at last follow-up (median, 8 months; range, 6-84 months). INTERPRETATION:Caspr2 is an autoantigen of encephalitis and PNH previously attributed to VGKC antibodies. The occurrence of other autoantibodies may result in a complex syndrome that at presentation could be mistaken for a motor neuron disorder. Recognition of this disorder is important, because it responds to immunotherapy.
Authors: S Poliak; L Gollan; R Martinez; A Custer; S Einheber; J L Salzer; J S Trimmer; P Shrager; E Peles Journal: Neuron Date: 1999-12 Impact factor: 17.173
Authors: Beau M Ances; Roberta Vitaliani; Robert A Taylor; David S Liebeskind; Alfredo Voloschin; David J Houghton; Steven L Galetta; Marc Dichter; Abass Alavi; Myrna R Rosenfeld; Josep Dalmau Journal: Brain Date: 2005-05-11 Impact factor: 13.501
Authors: Kevin A Strauss; Erik G Puffenberger; Matthew J Huentelman; Steven Gottlieb; Seth E Dobrin; Jennifer M Parod; Dietrich A Stephan; D Holmes Morton Journal: N Engl J Med Date: 2006-03-30 Impact factor: 91.245
Authors: Sarosh R Irani; Sian Alexander; Patrick Waters; Kleopas A Kleopa; Philippa Pettingill; Luigi Zuliani; Elior Peles; Camilla Buckley; Bethan Lang; Angela Vincent Journal: Brain Date: 2010-07-27 Impact factor: 13.501
Authors: L Brimberg; S Mader; V Jeganathan; R Berlin; T R Coleman; P K Gregersen; P T Huerta; B T Volpe; B Diamond Journal: Mol Psychiatry Date: 2016-10-04 Impact factor: 15.992
Authors: Zhuoyang Lu; M V V V Sekhar Reddy; Jianfang Liu; Ana Kalichava; Jiankang Liu; Lei Zhang; Fang Chen; Yun Wang; Luis Marcelo F Holthauzen; Mark A White; Suchithra Seshadrinathan; Xiaoying Zhong; Gang Ren; Gabby Rudenko Journal: J Biol Chem Date: 2016-09-12 Impact factor: 5.157
Authors: Mar Petit-Pedrol; Thaís Armangue; Xiaoyu Peng; Luis Bataller; Tania Cellucci; Rebecca Davis; Lindsey McCracken; Eugenia Martinez-Hernandez; Warren P Mason; Michael C Kruer; David G Ritacco; Wolfgang Grisold; Brandon F Meaney; Carmen Alcalá; Peter Sillevis-Smitt; Maarten J Titulaer; Rita Balice-Gordon; Francesc Graus; Josep Dalmau Journal: Lancet Neurol Date: 2014-01-22 Impact factor: 44.182